
    
      The maximum study duration per patient will be approximately 41 weeks: an up to 14-week
      screening period (consisting of an up to 2-week screening phase and a 12-week run-in phase),
      a 26-week randomized treatment period, and a 3-day post-treatment safety follow-up period.
    
  